Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors

Cancer Research

Volumn 63, Issue 19, 2003, Pages 6395-6404

  Von Bubnoff, Nikolas ^a   Veach, Darren R ^b   Miller, W Todd ^c   Li, Wanqing ^c   Sänger, Jana ^a   Peschel, Christian ^a   Bornmann, William G ^b   Clarkson, Bayard ^b   Duyster, Justus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; IMATINIB; PD 173956; PD 173958; PHOSPHOTRANSFERASE INHIBITOR; PYRIDO[2,2 D]PYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SKI DV 1 10; SKI DV 2 43; SKI DV 2 47; SKI DV 2 87; SKI DV 2 89; SKI DV M016; SKI DV M017; SKI DV S 43; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME CONFORMATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL LINE, TRANSFORMED; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MICE; PIPERAZINES; POINT MUTATION; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES;

EID: 0141953998     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Nowell, P. C., and Hungerford, D. A minute chromosome in human granulocytic leukaemia. Science (Wash. DC), 132: 1497-1501, 1960.
2. Rowley, J. D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (Lond.), 243: 290-293, 1973.
3. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., and Kantarjian, H. M. The biology of chronic myeloid leukemia. N. Engl. J. Med., 341: 164-172, 1999.
4. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med., 340: 1330-1340, 1999.
5. Daley, G. Q., Van Etten, R. A., and Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (Wash. DC), 247: 824-830, 1990.
6. Lugo, T. G., Pendergast, A. M., Muller, A. J., and Witte, O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (Wash. DC), 247: 1079-1082, 1990.
7. Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., and Lydon, N. B. Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett., 7: 187-192, 1997.
8. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B. J., and Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56: 100-104, 1996.
9. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
10. Beran, M., Cao, X., Estrov, Z., Jeha, S., Jin, G., O'Brien, S., Talpaz, M., Arlinghaus, R. B., Lydon, N. B., and Kantarjian, H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190, 000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res., 4: 1661-1672, 1998.
11. le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., and Gambacorti-Passerini, C. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst., 91: 163-168, 1999.
12. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
13. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., Druker, B., Goldman, J., O'Brien, S. G., Russell, N., Fischer, T., Ottmann, O., Cony-Makhoul, P., Facon, T., Stone, R., Miller, C., Tallman, M., Brown, R., Schuster, M., Loughran, T., Gratwohl, A., Mandelli, F., Saglio, G., Lazzarino, M., Russo, D., Baccarani, M., and Morra, E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346: 645-652, 2002.
14. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344: 1038-1042, 2001.
15. Talpaz, M., Silver, R. T., Druker, B. J., Goldman, J. M., Gambacorti-Passerini, C., Guilhot, F., Schiffer, C. A., Fischer, T., Deininger, M. W., Lennard, A. L., Hochhaus, A., Ottmann, O. G., Gratwohl, A., Baccarani, M., Stone, R., Tura, S., Mahon, F. X., Fernandes-Reese, S., Gathmann, I., Capdeville, R., Kantarjian, H. M., and Sawyers, C. L. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 99: 1928-1937, 2002.
16. Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., Ottmann, O. G., Schiffer, C. A., Talpaz, M., Guilhot, F., Deininger, M. W., Fischer, T., O'Brien, S. G., Stone, R. M., Gambacorti-Passerini, C. B., Russell, N. H., Reiffers, J. J., Shea, T. C., Chapuis, B., Coutre, S., Tura, S., Morra, E., Larson, R. A., Saven, A., Peschel, C., Gratwohl, A., Mandelli, F., Ben Am, M., Gathmann, I., Capdeville, R., Paquette, R. L., and Druker, B. J. Imatinib induces hematologic and cytogenetic responses in patients with chronic myclogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 99: 3530-3539, 2002.
17. Ottmann, O. G., Druker, B. J., Sawyers, C. L., Goldman, J. M., Reiffers, J., Silver, R. T., Tura, S., Fischer, T., Deininger, M. W., Schiffer, C. A., Baccarani, M., Gratwohl, A., Hochhaus, A., Hoelzer, D., Fernandes-Reese, S., Gathmann, I., Capdeville, R., and O'Brien, S. G. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 100: 1965-1971, 2002.
18. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash. DC), 293: 876-880, 2001.
19. Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., and Hughes, T. P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99: 3472-3475, 2002.
20. von Bubnoff, N., Schneller, F., Peschel, C., and Duyster, J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet, 359: 487-491, 2002.
21. Hofmann, W. K., Jones, L. C., Lemp, N. A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O. G., and Koeffler, H. P. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood, 99: 1860-1862, 2002.
22. Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Lai, J. L., Philippe, N., Facon, T., Fenaux, P., and Preudhomme, C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 100: 1014-1018, 2002.
23. Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., and Sawyers, C. L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2: 117-125, 2002.
24. Hochhaus, A., Kreil, S., Corbin, A. S., La Rosee, P., Muller, M. C., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N. C., Berger, U., Gschaidmeier, H., Druker, B. J., and Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (Baltimore), 16: 2190-2196, 2002.
25. von Bubnoff, N., Peschel, C., and Duyster, J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia (Baltimore), 17: 829-838, 2003.
26. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., and Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (Wash. DC), 289: 1938-1942, 2000.
27. Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T., Veach, D. R., Miller, W. T., Clarkson, B., and Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res., 62: 4236-4243, 2002.
28. Barthe, C., Cony-Makhoul, P., Melo, J. V., and Mahon, J. R. Roots of clinical resistance to STI-571 cancer therapy. Science (Wash. DC), 293: 2163, 2001.
29. Hochhaus, A., Kreil, S., Corbin, A., La Rosee, P., Lahaye, T., Berger, U., Cross, N. C., Linkesch, W., Druker, B. J., Hehlmann, R., Gambacorti-Passerini, C., Corneo, G., and D'Incalci, M. Roots of clinical resistance to STI-571 cancer therapy. Science (Wash. DC), 293: 2163, 2001.
30. Roumiantsev, S., Shah, N. P., Gorre, M. E., Nicoll, J., Brasher, B. B., Sawyers, C. L., and Van Etten, R. A. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA, 99: 10700-10705, 2002.
31. Manley, P., Cowan-Jacob, S. W., Fabbro, D., Fendrich, G., Furet, P., Guez, V., Liebetanz, J., Mestan, J., and Meyer, T. Molecular interactions between Glivec and isoforms of the kinase domain of c-Abl kinase. Proc. Am. Assoc. Cancer Res., 43: 4196, 2002.
32. Corbin, A. S., La Rosee, P., Stoffregen, E. P., Druker, B. J., and Deininger, M. W. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood, 2003.
33. Azam, M., Latek, R. R., and Daley, G. Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell, 112: 831-843, 2003.
34. Boschelli, D. H., Wu, Z., Klutchko, S. R., Showalter, H. D., Hamby, J. M., Lu, G. H., Major, T. C., Dahring, T. K., Batley, B., Panek, R. L., Keiser, J., Hartl, B. G., Kraker, A. J., Klohs, W. D., Roberts, B. J., Patmore, S., Elliott, W. L., Steinkampf, R., Bradford, L. A., Hallak, H., and Doherty, A. M. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2, 3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors. J. Med. Chem., 41: 4365-4377, 1998.
35. Klutchko, S. R., Hamby, J. M., Boschelli, D. H., Wu, Z., Kraker, A. J., Amar, A. M., Hartl, B. G., Shen, C., Klohs, W. D., Steinkampf, R. W., Driscoll, D. L., Nelson, J. M., Elliott, W. L., Roberts, B. J., Stoner, C. L., Vincent, P. W., Dykes, D. J., Panek, R. L., Lu, G. H., Major, T. C., Dahring, T. K., Hallak, H., Bradford, L. A., Showalter, H. D., and Doherty, A. M. 2-Substituted aminopyrido[2, 3d]pyrimidin-3(8H)-ones-structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J. Med. Chem., 41: 3276-3292, 1998.
36. Kraker, A. J., Hartl, B. G., Amar, A. M., Barvian, M. R., Showalter, H. D., and Moore, C. W. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem. Pharmcol., 60: 885-898, 2000.
37. Moasser, M. M., Srethapakdi, M., Sachar, K. S., Kraker, A. J., and Rosen, N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res., 59: 6145-6152, 1999.
38. Wisniewski, D., Lambek, C. L., Liu, C., Strife, A., Veach, D. R., Nagar, B., Young, M. A., Schindler, T., Bornmann, W. G., Bertino, J. R., Kuriyan, J., and Clarkson, B. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res., 62: 4244-4255, 2002.
39. Dorsey, J. F., Jove, R., Kraker, A. J., and Wu, J. The pyrido[2, 3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res., 60: 3127-3131, 2000.
40. Veach, D. R., Swendeman, S., Nagar, B., Wisniewski, D., Strife, A., Lambek, C. L., Liu, C., Li, W. W., Bornmann, W. G., Kuriyan, J., Bertino, J. R., and Clarkson, B. Towards picomolar inhibition of Bcr-Abl: synthesis and evaluation of a focused library of pyrido-[2, 3-d]-pyrimidine tyrosine kinase inhibitors guided by X-ray crystallography and molecular modeling. Proc. Am. Assoc. Cancer Res., 43: 847, 2002.
41. Veach, D. R., Lambek, C., Liu, C., Beresten, T., Wisniewski, D., Li, W., Wolff, N. C., Ilaria, R. L., Jr., Gelovani, J., Bornmann, W. G., and Clarkson, B. D. Synthesis, in silico, in vitro and in vivo characterization of pyrido[2, 3-d]-pyrimidine tyrosine kinase inhibitors. Proc. Am. Assoc. Cancer Res., 44: 3978, 2003.
42. Strife, A., Wisniewski, D., Liu, C., Lambek, C. L., Darzynkiewicz, Z., Silver, R. T., and Clarkson, B. Direct evidence that BCR-ABL tyrosine kinase activity disrupts normal synergistic interactions between kit ligand and cytokines in primary primitive progenitor cells. Mol. Cancer Res., 1: 176-185, 2003.
43. Hantgchel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., and Superti-Furga, G. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell, 112: 845-857, 2003.
44. Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., and Kuriyan, J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell, 112: 859-871, 2003.
45. Bai, R. Y., Ouyang, T., Miething, C., Morris, S. W., Peschel, C., and Duyster, J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood, 96: 4319-4327, 2000.
46. Duyster, J., Baskaran, R., and Wang, J. Y. Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Proc. Natl. Acad. Sci. USA, 92: 1555-1559, 1995.
47. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Wash. DC), 267: 1782-1788, 1995.
48. Gambacorti-Passerini, C., le Coutre, P., Mologni, L., Fanelli, M., Bertazzoli, C., Marchesi, E., Di Nicola, M., Biondi, A., Corneo, G. M., Belotti, D., Pogliani, E., and Lydon, N. B. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis., 23: 380-394, 1997.
49. An, W. G., Schulte, T. W., and Neckers, L. M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ., 11: 355-360, 2000.
50. Blagosklonny, M. V., Fojo, T., Bhalla, K. N., Kim, J. S., Trepel, J. B., Figg, W. D., Rivera, Y., and Neckers, L. M. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia (Baltimore), 15: 1537-1543, 2001.
51. Nimmanapalli, R., O'Bryan, E., and Bhalla, K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res., 61: 1799-1804, 2001.
52. Nimmanapalli, R., O'Bryan, E., Huang, M., Bali, P., Burnette, P. K., Loughran, T., Tepperberg, J., Jove, R., and Bhalla, K. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxy-geldanamycin. Cancer Res., 62: 5761-5769, 2002.
53. Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N., and Sawyers, C. L. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood, 100: 3041-3044, 2002.
54. Huron, D. R., Gorre, M. E., Kraker, A. J., Sawyers, C. L., Rosen, N., and Moasser, M. M. A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin. Cancer Res., 9: 1267-1273, 2003.
55. Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., Seymour, J. F., Arthur, C., Joske, D., Lynch, K., and Hughes, T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood, prepublished online March 6, 2003; DOI 10.1182/blood-2002-09-2896: 2003.
56. Druker, B. J., and Mauro, M. J. STI571: targeting BCR-ABL as therapy for CML. Oncologist., 6: 233-238, 2001.
57. Allen, P. B., and Wiedemann, L. M. An activating mutation in the ATP binding site of the ABL kinase domain. J. Biol. Chem., 271: 19585-19591, 1996.
58. Corbin, A. S., Buchdunger, E., Pascal, F., and Druker, B. J. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571: J. Biol. Chem., 277: 32214-32219, 2002.
59. La Rosee, P., Corbin, A. S., Stoffregen, E. P., Deininger, M. W., and Druker, B. J. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res., 62: 7149-7153, 2002.